The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy
Open Forum Infect Dis. 2023 Nov 14;10(11):ofad551. doi: 10.1093/ofid/ofad551.eCollection 2023 Nov.
1Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
2Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
3Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
4Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Abstract
Hepatitis B virus (HBV) core antigen antibodies passively transferred from immunoglobulin products used for replacement or immunomodulation may lead to unnecessary antiviral treatment for patients who are also starting immunosuppressive treatment. We have systematically assessed the contents of 93 commercial immunoglobulin batches and show that there are consistent product-specific differences in the levels of HBV core antigen antibodies and that choice of immunoglobulin product may have an impact on false-positivity rates.
Stay Informed!
